25. Segment information
The Group’s activities are managed and operated in one segment, biopharmaceuticals. There is no other significant class of business, either individual or in aggregate. As such, the chief operating decision maker (i.e., the CEO) reviews the operating results and operating plans and makes resource allocation decisions on a company-wide basis.
Geographical information
Revenue of 2017 from continuing operations are mainly related to grants and other operating income 0.6 million euros Spain and 0.3 million euros Belgium.
The Group’s non-current assets by location are presented below:
|
|
|
As at December 31, |
|
||||
|
Thousands of euros |
|
2017 |
|
2016 |
|
2015 |
|
|
Belgium |
|
142 |
|
154 |
|
2,159 |
|
|
Spain |
|
42,282 |
|
51,927 |
|
52,082 |
|
|
|
|
|
|
|
|
|
|
|
Total |
|
42,424 |
|
52,081 |
|
54,241 |
|
|
|
|
|
|
|
|
|
|